14 results about "Transcript level" patented technology

The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels in plants, and plants containing such promoters or promoter control elements.

This invention relates to oligonucleotide compositions and methods for using the same. [Solution] In particular, this disclosure provides designed oligonucleotides, compositions thereof and methods of use. In some embodiments, this disclosure provides techniques useful for reducing transcript levels. In some embodiments, this disclosure provides techniques useful for modulating transcript splicing. In some embodiments, the techniques provided can alter the splicing of dystrophin (DMD) transcripts. In some embodiments, this disclosure provides methods for treating diseases such as Duchenne muscular dystrophy and Becker muscular dystrophy.

The application belongs to the technical field of biology, and particularly relates to a dsRNA of a target Helicoverpa armigera HaPburs gene and application thereof in prevention and treatment of the Helicoverpa armigera. HaPburs RNA interference mediated knockdown reduces the transcript level by 60.01%, and induces morphological abnormalities of pheromone glands (PG), which are irregular black protrusions; the silencing HaPburs reduces the main pheromone component Z 11-16: Ald content, while the male insect attraction rate and mating rate, cumulative egg production also significantly decrease, and the transcript level of the sex pheromone biosynthesis related genes HaPKA and HaACC is also significantly reduced. It is shown that HaPburs the genes participate in PG morphogenesis and regulate sex pheromone biosynthesis through a cAMP-PKA-ACC regulatory axis, thereby affecting the reproductive communication of the Helicoverpa armigera. The application provides a novel target and technical scheme for green and efficient prevention and control of the Helicoverpa armigera, and has important research and development value and application prospect.

This invention discloses the artificial synthesis of the disease-resistant gene NLP27 and its application, belonging to the field of plant genetic engineering technology. This invention selects a conserved 27-amino acid fragment from Verticillium dahliae NLP1, modifies its nucleotide sequence, and synthesizes the NLP27 gene, which is then overexpressed in potato plants through genetic transformation. Inoculation analysis shows that transgenic plants with the NLP27 gene exhibit high resistance to potato late blight and scab. Quantitative PCR analysis shows that excessively high NLP27 transcript levels significantly inhibit potato plant growth. After screening for expression levels and disease resistance, three transgenic lines with moderate NLP27 expression levels (such as PT1, PT6, and PT7) were obtained. These lines significantly enhanced resistance to potato late blight and scab without sacrificing yield.

The present disclosure relates to the technical field of cell culture. It provides a method that facilitates the selection of single cell clones or cell pools for the manufacture of antigen binding proteins having two to four different antibody chains. The method utilizes ddPCR to quantify the transcript level.

Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as pancreatic transplant recipients, pancreatic and kidney transplant recipients, and simultaneous pancreatic and kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA) or each an independent assessment of the mRNA transcript level as well as an independent assessment of the dd-cfDNA. Genes that correlate with pancreatic transplant rejection in simultaneous pancreatic and kidney transplant recipients are also disclosed.

A cell-based screening system and method for identifying compounds that selectively modulate the expression of CAG repeat-containing RNA associated with spinocerebellar ataxias and related disorders. The system comprises a human HEK293T cell line engineered to co-express two reporter constructs: a CAG repeat-expanded polyglutamine-nanoluciferase fusion protein with at least 60 CAG repeats, and a control firefly luciferase with no CAG repeats. Each construct contains a unique probe-binding sequence downstream of the repeat region, enabling independent quantification via multiplex RT-qPCR with fluorescent probes, as well as dual luciferase assays. The cell line is optimized for high-throughput screening to identify therapeutic compounds that reduce pathogenic CAG repeat RNA levels while sparing control transcripts. The invention further encompasses methods for screening, validating, and identifying candidate therapeutics for CAG expansion disorders, including spinocerebellar ataxias and Huntington's disease.

Nucleic acid delivery vehicles for delivering nucleic acid, e.g., for RNAi to cells that are typically refractory to RNAi by using extracellular vesicles (EVs) from cultured beetle cells as delivery vehicles. Instead of using high levels of long dsRNA and transfection reagents to accomplish suppression of an mRNA target in cells that don't respond to treatment with naked dsRNA, this approach applies the dsRNA to cultured beetle cells, collects nucleic-acid loaded EVs from the culture, then treats our target cells with the intracellularly loaded EVs, which results in significant enhancement of the RNAi response and greater suppression of transcript levels.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting the expression of a chicken RASGRP3 (Reduced Amplification of Sequence Growth Protein 3) gene and application of the siRNA, the siRNA comprises a positive-sense strand and an antisense strand, and is any one of RASGRP3-Anas-214, RASGRP3-Anas-846 and RASGRP3-Anas-1187. According to the specific siRNA aiming at the chicken RASGRP3 mRNA provided by the invention, in a chicken liver cancer cell line (LMH), after liposome-mediated transfection culture is performed for 48 hours, RT-qPCR is adopted to evaluate the transcript level, and a result shows that the relative expression quantity of the chicken RASGRP3 mRNA is remarkably reduced compared with that of negative control, and the repeatability is good. The polypeptide can be further used for inhibiting ALV-J replication, provides a new molecular intervention target for prevention and control of avian leukosis, and has important scientific research and potential economic values.

The invention provides a translation product prediction method and system based on multi-dimensional feature integration. According to the method, by introducing a codon-level prediction strategy and combining biological characteristics such as Kozak sequence scores, codon adaptation indexes and GC content, a Bayesian scoring framework is constructed, and the accuracy and reliability of translation product prediction are systematically improved. Compared with the existing prediction system, the system provided by the invention has the advantages that incomplete recognition errors can be reduced by about 85%, the prediction accuracy of the complete ORF is improved from 86.35% to 94.04%, and the false positive rate at the NR transcript level is reduced from 18.00% to 12.78%. The method and the system have application prospects in the fields of gene expression regulation and control research and tumor immunotherapy.

The present invention provides methods of using the RNA analysis to identify a cell type from which a midbody remnant (MBR) originated. The methods include isolating MBR, analyzing the RNA in the MBR to determine RNA transcript levels, and using the RNA transcript levels to identify a cell type from which the MBR originated. The method may be used to detect proliferative diseases including cancer by comparing RNA transcript levels to control levels.

The present invention is directed to promoter sequences and promoter control elements, polynucleotide constructs comprising the promoters and control elements, and methods of identifying the promoters, control elements, or fragments thereof. The invention further relates to the use of the present promoters or promoter control elements to modulate transcript levels in plants, and plants containing such promoters or promoter control elements.

The present invention relates to the technical field of bioinformatics, and particularly to a method for identifying transposable element-derived RNAs based on RNA sequencing data. The present invention proposes to take the exon level of teRNAs as the analysis object. Compared with the teRNA locus, the teRNA exon not only achieves more accurate locus identification, but also retains the form of the TE in the transcript, including whether it provides splicing sites and polyadenylation signals, and whether it is chimeric with genes or other TE loci. And compared with the teRNA transcript level, as a component of the transcript, the teRNA exon significantly reduces the sequence assembly difficulty of short-read sequencing data. The present invention combines Bayesian models, reference-based assembly algorithms, and local de novo assembly algorithms, and through the mutual correction of different assembly algorithms and repeated alignment of sequencing reads before and after assembly, reduces the false positives of assembly, thereby improving the accuracy of teRNA identification.

The invention relates to inhibitors of MSI2 functions that are able to decrease MSI2 activity, MSI2 transcript levels or MSI2 protein levels in myotonic dystrophy cells or cells with MD phenotype, wherein said inhibitor is for use in the treatment of myotonic dystrophy in a mammal.